Clinical Trial

A Phase II Trial of Bicalutamide in Patients Receiving Intravesical BCG for Non-muscle Invasive Bladder Cancer

Study acronym: BicaBCa
Recruiting Phase 2
View on ClinicalTrials.gov →
Summary
This is a phase II randomized controlled clinical trial comparing standard induction BCG versus bicalutamide and standard induction BCG among patients with non-muscle invasive bladder cancer.
Protocol Amendment History 10 amendments
This ClinicalTrials.gov record has been amended 10 times since 2022-04-07; most recent amendment 2025-12-17.
Status change: Not Yet Recruiting → Recruiting 2022-07-13
Trial Details
NCT Number NCT05327647
Lead Sponsor CHU de Quebec-Universite Laval
Collaborators: Canadian Institutes of Health Research (CIHR), Cancer Research Society
Conditions Non-Muscle Invasive Bladder Cancer
Enrollment 160 participants
Start Date 2022-06-23
Primary Completion 2026-09-01 (estimated)
Study Completion 2026-12-31 (estimated)
Updated on ClinicalTrials.gov 2025-12-18